Advertisement

pp 1-23 | Cite as

CGRP in Animal Models of Migraine

  • Anne-Sophie Wattiez
  • Mengya Wang
  • Andrew F. RussoEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of migraine patients is beginning. However, there are still many unknowns in terms of CGRP mechanisms of action that need to be elucidated to allow new advances in migraine therapies. CGRP has been studied both clinically and preclinically since its discovery. Here we review some of the preclinical data regarding CGRP in animal models of migraine.

Keywords

Animal model Antibody CGRP Migraine 

Notes

Acknowledgments

The authors thank members of the lab for their comments and support from Dept. Defense W81XWH-16-1-0071, W81XWH-16-1-0211; VA-ORD (RR&D) 1IO1RX002101; C6810-C and NIH NS075599.

References

  1. Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115:1–4.  https://doi.org/10.1016/j.pain.2005.03.008CrossRefGoogle Scholar
  2. Akerman S, Holland PR, Hoffmann J (2013) Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception. Cephalalgia 33:577–592.  https://doi.org/10.1177/0333102412472071CrossRefGoogle Scholar
  3. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240–244Google Scholar
  4. Asghar MS et al (2010) Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 75:1520–1526.  https://doi.org/10.1212/WNL.0b013e3181f9626aCrossRefGoogle Scholar
  5. Asghar MS et al (2011) Evidence for a vascular factor in migraine. Ann Neurol 69:635–645.  https://doi.org/10.1002/ana.22292CrossRefGoogle Scholar
  6. Bates EA et al (2010) Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30:170–178.  https://doi.org/10.1111/j.1468-2982.2009.01864.xCrossRefGoogle Scholar
  7. Bellamy JL, Cady RK, Durham PL (2006) Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46:24–33.  https://doi.org/10.1111/j.1526-4610.2006.00294.xCrossRefGoogle Scholar
  8. Bennett AD, Chastain KM, Hulsebosch CE (2000) Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain 86:163–175Google Scholar
  9. Bhatt DK, Gupta S, Ploug KB, Jansen-Olesen I, Olesen J (2014) mRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neurosci Lett 559:99–104.  https://doi.org/10.1016/j.neulet.2013.11.057CrossRefGoogle Scholar
  10. Bhatt DK, Ramachandran R, Christensen SL, Gupta S, Jansen-Olesen I, Olesen J (2015) CGRP infusion in unanesthetized rats increases expression of c-Fos in the nucleus tractus solitarius and caudal ventrolateral medulla, but not in the trigeminal nucleus caudalis. Cephalalgia 35:220–233.  https://doi.org/10.1177/0333102414535995CrossRefGoogle Scholar
  11. Bohn KJ et al (2017) CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1. Br J Pharmacol 174:1826–1840.  https://doi.org/10.1111/bph.13783CrossRefGoogle Scholar
  12. Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Geraud G (2010) Photophobia in migraine: an interictal PET study of cortical hyperexcitability and its modulation by pain. J Neurol Neurosurg Psychiatry 81:978–984.  https://doi.org/10.1136/jnnp.2009.190223CrossRefGoogle Scholar
  13. Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL (2006) Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96:65–77.  https://doi.org/10.1111/j.1471-4159.2005.03524.xCrossRefGoogle Scholar
  14. Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84:903–934.  https://doi.org/10.1152/physrev.00037.2003CrossRefGoogle Scholar
  15. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54–56Google Scholar
  16. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 87:533–536Google Scholar
  17. Burgos Vega C, Quigley L, Patel M, Price T, Arkopian A, Dussor G (2017) Meningeal application of prolactin and CGRP produces female specific migraine-related behavior in rodents. J Pain 18:S11Google Scholar
  18. Capuano A, Greco MC, Navarra P, Tringali G (2014) Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization. Eur J Pharmacol 740:97–102.  https://doi.org/10.1016/j.ejphar.2014.06.046CrossRefGoogle Scholar
  19. Carlton SM, Westlund KN, Zhang DX, Sorkin LS, Willis WD (1990) Calcitonin gene-related peptide containing primary afferent fibers synapse on primate spinothalamic tract cells. Neurosci Lett 109:76–81Google Scholar
  20. Chrissobolis S, Zhang Z, Kinzenbaw DA, Lynch CM, Russo AF, Faraci FM (2010) Receptor activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-related peptide and inhibits angiotensin II-induced vascular dysfunction. Stroke 41:2329–2334.  https://doi.org/10.1161/STROKEAHA.110.589648CrossRefGoogle Scholar
  21. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J (1999) Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 19:660–667. Discussion 626.  https://doi.org/10.1046/j.1468-2982.1999.019007660.xCrossRefGoogle Scholar
  22. Chu DQ, Choy M, Foster P, Cao T, Brain SD (2000) A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13-52) to modulate microvascular but not thermal hyperalgesia responses. Br J Pharmacol 130:1589–1596.  https://doi.org/10.1038/sj.bjp.0703502CrossRefGoogle Scholar
  23. Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2018) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 333102418774299.  https://doi.org/10.1177/0333102418774299
  24. Colonna DM, Meng W, Deal DD, Busija DW (1994) Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits. Am J Physiol 266:H1095–H1102.  https://doi.org/10.1152/ajpheart.1994.266.3.H1095CrossRefGoogle Scholar
  25. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ (1999) Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 126:1478–1486.  https://doi.org/10.1038/sj.bjp.0702444CrossRefGoogle Scholar
  26. Cutrer FM, Huerter K (2007) Migraine aura. Neurologist 13:118–125.  https://doi.org/10.1097/01.nrl.0000252943.82792.38CrossRefGoogle Scholar
  27. Devesa I, Ferrandiz-Huertas C, Mathivanan S, Wolf C, Lujan R, Changeux JP, Ferrer-Montiel A (2014) alphaCGRP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors. Proc Natl Acad Sci U S A 111:18345–18350.  https://doi.org/10.1073/pnas.1420252111CrossRefGoogle Scholar
  28. Durham PL, Russo AF (2002) New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther 94:77–92Google Scholar
  29. Edelmayer RM et al (2009) Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol 65:184–193.  https://doi.org/10.1002/ana.21537CrossRefGoogle Scholar
  30. Edvinsson L (1985) Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci 8:126–131Google Scholar
  31. Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57(Suppl 2):47–55.  https://doi.org/10.1111/head.13081CrossRefGoogle Scholar
  32. Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150:633–640.  https://doi.org/10.1038/sj.bjp.0707134CrossRefGoogle Scholar
  33. Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 14:338–350.  https://doi.org/10.1038/s41582-018-0003-1CrossRefGoogle Scholar
  34. Escott KJ, Beattie DT, Connor HE, Brain SD (1995) Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide. Brain Res 669:93–99Google Scholar
  35. Feistel S, Albrecht S, Messlinger K (2013) The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion. J Headache Pain 14:93.  https://doi.org/10.1186/1129-2377-14-93CrossRefGoogle Scholar
  36. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM (2015) Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol 14:65–80.  https://doi.org/10.1016/S1474-4422(14)70220-0CrossRefGoogle Scholar
  37. Filiz A, Tepe N, Eftekhari S, Boran HE, Dilekoz E, Edvinsson L, Bolay H (2017) CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia 333102417735845.  https://doi.org/10.1177/0333102417735845
  38. Gangula PR et al (2000) Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. Hypertension 35:470–475Google Scholar
  39. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56.  https://doi.org/10.1002/ana.410330109CrossRefGoogle Scholar
  40. Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117(Pt 3):427–434Google Scholar
  41. Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193–196.  https://doi.org/10.1002/ana.410230214CrossRefGoogle Scholar
  42. Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187.  https://doi.org/10.1002/ana.410280213CrossRefGoogle Scholar
  43. Guo S, Vollesen ALH, Olesen J, Ashina M (2016) Premonitory and non-headache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain 157:2773–2781.  https://doi.org/10.1097/j.pain.0000000000000702CrossRefGoogle Scholar
  44. Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179–1186.  https://doi.org/10.1177/0333102410368444CrossRefGoogle Scholar
  45. Hokfelt T et al (1992) Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems. Ann N Y Acad Sci 657:119–134Google Scholar
  46. Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC (2000) Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res 873:54–59Google Scholar
  47. Ishida-Yamamoto A, Tohyama M (1989) Calcitonin gene-related peptide in the nervous tissue. Prog Neurobiol 33:335–386Google Scholar
  48. Jiang L, Wang Y, Xu Y, Ma D, Wang M (2018) The transient receptor potential ankyrin type 1 plays a critical role in cortical spreading depression. Neuroscience 382:23–34.  https://doi.org/10.1016/j.neuroscience.2018.04.025CrossRefGoogle Scholar
  49. Kaiser EA, Kuburas A, Recober A, Russo AF (2012) Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist. J Neurosci 32:15439–15449.  https://doi.org/10.1523/JNEUROSCI.3265-12.2012CrossRefGoogle Scholar
  50. Kaiser EA, Rea BJ, Kuburas A, Kovacevich BR, Garcia-Martinez LF, Recober A, Russo AF (2017) Anti-CGRP antibodies block CGRP-induced diarrhea in mice. Neuropeptides 64:95–99.  https://doi.org/10.1016/j.npep.2016.11.004CrossRefGoogle Scholar
  51. Kawamura M, Kuraishi Y, Minami M, Satoh M (1989) Antinociceptive effect of intrathecally administered antiserum against calcitonin gene-related peptide on thermal and mechanical noxious stimuli in experimental hyperalgesic rats. Brain Res 497:199–203Google Scholar
  52. Kelman L (2004) The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 44:865–872.  https://doi.org/10.1111/j.1526-4610.2004.04168.xCrossRefGoogle Scholar
  53. Kelman L (2007) The triggers or precipitants of the acute migraine attack. Cephalalgia 27:394–402.  https://doi.org/10.1111/j.1468-2982.2007.01303.xCrossRefGoogle Scholar
  54. Kopruszinski CM et al (2017) Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia 37:560–570.  https://doi.org/10.1177/0333102416650702CrossRefGoogle Scholar
  55. Koulchitsky S, Fischer MJ, Messlinger K (2009) Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 29:408–417.  https://doi.org/10.1111/j.1468-2982.2008.01745.xCrossRefGoogle Scholar
  56. Kuraishi Y, Nanayama T, Ohno H, Minami M, Satoh M (1988) Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide. Neurosci Lett 92:325–329Google Scholar
  57. Kurosawa M, Messlinger K, Pawlak M, Schmidt RF (1995) Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 114:1397–1402Google Scholar
  58. Lappe RW, Slivjak MJ, Todt JA, Wendt RL (1987) Hemodynamic effects of calcitonin gene-related peptide in conscious rats. Regul Pept 19:307–312Google Scholar
  59. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61.  https://doi.org/10.1046/j.1468-2982.2002.00310.xCrossRefGoogle Scholar
  60. Lee Y et al (1985) Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis. Brain Res 330:194–196Google Scholar
  61. Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705.  https://doi.org/10.1002/ana.20619CrossRefGoogle Scholar
  62. Li N, Lundeberg T, Yu LC (2001) Involvement of CGRP and CGRP1 receptor in nociception in the nucleus accumbens of rats. Brain Res 901:161–166Google Scholar
  63. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group AA (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349.  https://doi.org/10.1212/01.wnl.0000252808.97649.21CrossRefGoogle Scholar
  64. Loder E (2010) Triptan therapy in migraine. N Engl J Med 363:63–70.  https://doi.org/10.1056/NEJMct0910887CrossRefGoogle Scholar
  65. LoPinto C, Young WB, Ashkenazi A (2006) Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 26:852–856.  https://doi.org/10.1111/j.1468-2982.2006.01121.xCrossRefGoogle Scholar
  66. Lu JT et al (1999) Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 14:99–120.  https://doi.org/10.1006/mcne.1999.0767CrossRefGoogle Scholar
  67. Luebke AE, Holt JC, Jordan PM, Wong YS, Caldwell JS, Cullen KE (2014) Loss of alpha-calcitonin gene-related peptide (alphaCGRP) reduces the efficacy of the Vestibulo-ocular Reflex (VOR). J Neurosci 34:10453–10458.  https://doi.org/10.1523/JNEUROSCI.3336-13.2014CrossRefGoogle Scholar
  68. Maison SF, Emeson RB, Adams JC, Luebke AE, Liberman MC (2003) Loss of alpha CGRP reduces sound-evoked activity in the cochlear nerve. J Neurophysiol 90:2941–2949.  https://doi.org/10.1152/jn.00596.2003CrossRefGoogle Scholar
  69. Marquez de Prado B, Hammond DL, Russo AF (2009) Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. J Pain 10:992–1000.  https://doi.org/10.1016/j.jpain.2009.03.018CrossRefGoogle Scholar
  70. Marti E et al (1987) Ontogeny of peptide- and amine-containing neurones in motor, sensory, and autonomic regions of rat and human spinal cord, dorsal root ganglia, and rat skin. J Comp Neurol 266:332–359.  https://doi.org/10.1002/cne.902660304CrossRefGoogle Scholar
  71. Martin VT, Behbehani MM (2001) Toward a rational understanding of migraine trigger factors. Med Clin North Am 85:911–941Google Scholar
  72. Mason BN, Kaiser EA, Kuburas A, Loomis MM, Latham JA, Garcia-Martinez LF, Russo AF (2017) Induction of migraine-like photophobic behavior in mice by both peripheral and central cgrp mechanisms. J Neurosci 37:204–216.  https://doi.org/10.1523/JNEUROSCI.2967-16.2016CrossRefGoogle Scholar
  73. Mathew NT, Kailasam J, Seifert T (2004) Clinical recognition of allodynia in migraine. Neurology 63:848–852Google Scholar
  74. Melo-Carrillo A, Noseda R, Nir RR, Schain AJ, Stratton J, Strassman AM, Burstein R (2017a) Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP. Antibody J Neurosci 37:7149–7163.  https://doi.org/10.1523/JNEUROSCI.0576-17.2017CrossRefGoogle Scholar
  75. Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J, Burstein R (2017b) Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (adelta) but not unmyelinated (C) meningeal nociceptors. J Neurosci 37:10587–10596.  https://doi.org/10.1523/JNEUROSCI.2211-17.2017CrossRefGoogle Scholar
  76. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF (1995) Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol 73:1020–1024Google Scholar
  77. Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C (1999) Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369:271–277Google Scholar
  78. Mogil JS et al (2005) Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci U S A 102:12938–12943.  https://doi.org/10.1073/pnas.0503264102CrossRefGoogle Scholar
  79. Mulleners WM, Aurora SK, Chronicle EP, Stewart R, Gopal S, Koehler PJ (2001) Self-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accurately. Headache 41:31–39Google Scholar
  80. Munro G, Petersen S, Jansen-Olesen I, Olesen J (2018) A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain. Sci Rep 8:1836.  https://doi.org/10.1038/s41598-018-19901-1CrossRefGoogle Scholar
  81. Nakamura-Craig M, Gill BK (1991) Effect of neurokinin A, substance P and calcitonin gene related peptide in peripheral hyperalgesia in the rat paw. Neurosci Lett 124:49–51Google Scholar
  82. Noseda R, Monconduit L, Constandil L, Chalus M, Villanueva L (2008) Central nervous system networks involved in the processing of meningeal and cutaneous inputs from the ophthalmic branch of the trigeminal nerve in the rat. Cephalalgia 28:813–824.  https://doi.org/10.1111/j.1468-2982.2008.01588.xCrossRefGoogle Scholar
  83. Oh-hashi Y et al (2001) Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ Res 89:983–990Google Scholar
  84. Oku R, Satoh M, Fujii N, Otaka A, Yajima H, Takagi H (1987) Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 403:350–354Google Scholar
  85. Ong JJY, Wei DY, Goadsby PJ (2018) Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 78:411–437.  https://doi.org/10.1007/s40265-018-0865-yCrossRefGoogle Scholar
  86. Oshinsky ML, Sanghvi MM, Maxwell CR, Gonzalez D, Spangenberg RJ, Cooper M, Silberstein SD (2012) Spontaneous trigeminal allodynia in rats: a model of primary headache. Headache 52:1336–1349.  https://doi.org/10.1111/j.1526-4610.2012.02247.xCrossRefGoogle Scholar
  87. Pecile A, Guidobono F, Netti C, Sibilia V, Biella G, Braga PC (1987) Calcitonin gene-related peptide: antinociceptive activity in rats, comparison with calcitonin. Regul Pept 18:189–199Google Scholar
  88. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 143:697–704.  https://doi.org/10.1038/sj.bjp.0705966CrossRefGoogle Scholar
  89. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005a) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202–213Google Scholar
  90. Petersen KA, Nilsson E, Olesen J, Edvinsson L (2005b) Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 25:424–432.  https://doi.org/10.1111/j.1468-2982.2005.00869.xCrossRefGoogle Scholar
  91. Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155:269–274.  https://doi.org/10.1016/j.pain.2013.10.004CrossRefGoogle Scholar
  92. Rasmussen BK (1993) Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53:65–72Google Scholar
  93. Rea BJ et al (2018) Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine. Pain.  https://doi.org/10.1097/j.pain.0000000000001337Google Scholar
  94. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF (2009) Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 29:8798–8804.  https://doi.org/10.1523/JNEUROSCI.1727-09.2009CrossRefGoogle Scholar
  95. Recober A, Kaiser EA, Kuburas A, Russo AF (2010) Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology 58:156–165.  https://doi.org/10.1016/j.neuropharm.2009.07.009CrossRefGoogle Scholar
  96. Reuter U et al (1998) Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Am J Physiol 274:H1979–H1987Google Scholar
  97. Rosenfeld MG et al (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129–135Google Scholar
  98. Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94:1099–1142.  https://doi.org/10.1152/physrev.00034.2013CrossRefGoogle Scholar
  99. Russo AF (2015a) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552.  https://doi.org/10.1146/annurev-pharmtox-010814-124701CrossRefGoogle Scholar
  100. Russo AF (2015b) CGRP as a neuropeptide in migraine: lessons from mice. Br J Clin Pharmacol 80:403–414.  https://doi.org/10.1111/bcp.12686CrossRefGoogle Scholar
  101. Russo AF, Kuburas A, Kaiser EA, Raddant AC, Recober A (2009) A potential preclinical migraine model: CGRP-sensitized mice. Mol Cell Pharmacol 1:264–270Google Scholar
  102. Sabharwal R, Zhang Z, Lu Y, Abboud FM, Russo AF, Chapleau MW (2010) Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates angiotensin-induced hypertension. Hypertension 55:627–635.  https://doi.org/10.1161/HYPERTENSIONAHA.109.148171CrossRefGoogle Scholar
  103. Salmon AM, Damaj I, Sekine S, Picciotto MR, Marubio L, Changeux JP (1999) Modulation of morphine analgesia in alphaCGRP mutant mice. Neuroreport 10:849–854Google Scholar
  104. Salmon AM, Damaj MI, Marubio LM, Epping-Jordan MP, Merlo-Pich E, Changeux JP (2001) Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 4:357–358.  https://doi.org/10.1038/86001CrossRefGoogle Scholar
  105. Satoh M, Kuraishi Y, Kawamura M (1992) Effects of intrathecal antibodies to substance P, calcitonin gene-related peptide and galanin on repeated cold stress-induced hyperalgesia: comparison with carrageenan-induced hyperalgesia. Pain 49:273–278Google Scholar
  106. Schorscher-Petcu A, Austin JS, Mogil JS, Quirion R (2009) Role of central calcitonin gene-related peptide (CGRP) in locomotor and anxiety- and depression-like behaviors in two mouse strains exhibiting a CGRP-dependent difference in thermal pain sensitivity. J Mol Neurosci 39:125–136.  https://doi.org/10.1007/s12031-009-9201-zCrossRefGoogle Scholar
  107. Senba E, Tohyama M (1988) Calcitonin gene-related peptide containing autonomic efferent pathways to the pelvic ganglia of the rat. Brain Res 449:386–390Google Scholar
  108. Siren AL, Feuerstein G (1988) Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat. J Pharmacol Exp Ther 247:69–78Google Scholar
  109. Skofitsch G, Jacobowitz DM (1985) Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system. Peptides 6:721–745Google Scholar
  110. Sowers LP, Tye AE, Russo AF (2017) Lessons learned from CGRP mutant mice. In: Dalkara T, Moskowitz MA (eds) Neurobiological basis of migraine, 1st edn. Wiley, HobokenGoogle Scholar
  111. Spierings EL, Ranke AH, Honkoop PC (2001) Precipitating and aggravating factors of migraine versus tension-type headache. Headache 41:554–558Google Scholar
  112. Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181.  https://doi.org/10.1038/sj.bjp.0705807CrossRefGoogle Scholar
  113. Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE, Berman NE (2011) Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 51:674–692.  https://doi.org/10.1111/j.1526-4610.2011.01882.xCrossRefGoogle Scholar
  114. Sun RQ, Lawand NB, Lin Q, Willis WD (2004) Role of calcitonin gene-related peptide in the sensitization of dorsal horn neurons to mechanical stimulation after intradermal injection of capsaicin. J Neurophysiol 92:320–326.  https://doi.org/10.1152/jn.00086.2004CrossRefGoogle Scholar
  115. Tassorelli C, Greco R, Wang D, Sandrini M, Sandrini G, Nappi G (2003) Nitroglycerin induces hyperalgesia in rats – a time-course study. Eur J Pharmacol 464:159–162Google Scholar
  116. Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1:73–80.  https://doi.org/10.1111/j.1468-1331.1994.tb00053.xCrossRefGoogle Scholar
  117. Troltzsch M, Denekas T, Messlinger K (2007) The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 562:103–110.  https://doi.org/10.1016/j.ejphar.2007.01.058CrossRefGoogle Scholar
  118. Tsujikawa K et al (2007) Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc Natl Acad Sci U S A 104:16702–16707.  https://doi.org/10.1073/pnas.0705974104CrossRefGoogle Scholar
  119. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62:131–136Google Scholar
  120. van Dongen RM et al (2017) Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia 37:49–63.  https://doi.org/10.1177/0333102415625614CrossRefGoogle Scholar
  121. Vos T et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2163–2196.  https://doi.org/10.1016/S0140-6736(12)61729-2CrossRefGoogle Scholar
  122. Wahl M, Schilling L, Parsons AA, Kaumann A (1994) Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res 637:204–210Google Scholar
  123. Wang Y, Li Y, Wang M (2016) Involvement of CGRP receptors in retinal spreading depression. Pharmacol Rep 68:935–938.  https://doi.org/10.1016/j.pharep.2016.05.001CrossRefGoogle Scholar
  124. Weidner C et al (2000) Acute effects of substance P and calcitonin gene-related peptide in human skin – a microdialysis study. J Invest Dermatol 115:1015–1020.  https://doi.org/10.1046/j.1523-1747.2000.00142.xCrossRefGoogle Scholar
  125. Wiesenfeld-Hallin Z, Hokfelt T, Lundberg JM, Forssmann WG, Reinecke M, Tschopp FA, Fischer JA (1984) Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat. Neurosci Lett 52:199–204Google Scholar
  126. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat – intravital microscope studies. Cephalalgia 17:525–531.  https://doi.org/10.1046/j.1468-2982.1997.1704525.xCrossRefGoogle Scholar
  127. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ (2001) The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 133:1029–1034.  https://doi.org/10.1038/sj.bjp.0704162CrossRefGoogle Scholar
  128. Xu W, Lundeberg T, Wang YT, Li Y, Yu LC (2003) Antinociceptive effect of calcitonin gene-related peptide in the central nucleus of amygdala: activating opioid receptors through amygdala-periaqueductal gray pathway. Neuroscience 118:1015–1022Google Scholar
  129. Yao G, Huang Q, Wang M, Yang CL, Liu CF, Yu TM (2017) Behavioral study of a rat model of migraine induced by CGRP. Neurosci Lett 651:134–139.  https://doi.org/10.1016/j.neulet.2017.04.059CrossRefGoogle Scholar
  130. Yisarakun W, Chantong C, Supornsilpchai W, Thongtan T, Srikiatkhachorn A, Reuangwechvorachai P, Maneesri-le Grand S (2015) Up-regulation of calcitonin gene-related peptide in trigeminal ganglion following chronic exposure to paracetamol in a CSD migraine animal model. Neuropeptides 51:9–16.  https://doi.org/10.1016/j.npep.2015.03.008CrossRefGoogle Scholar
  131. Yu LC, Weng XH, Wang JW, Lundeberg T (2003) Involvement of calcitonin gene-related peptide and its receptor in anti-nociception in the periaqueductal grey of rats. Neurosci Lett 349:1–4Google Scholar
  132. Zagami AS, Goadsby PJ, Edvinsson L (1990) Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16:69–75Google Scholar
  133. Zhang L, Hoff AO, Wimalawansa SJ, Cote GJ, Gagel RF, Westlund KN (2001) Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 89:265–273Google Scholar
  134. Zhang Z, Dickerson IM, Russo AF (2006) Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology 147:1932–1940.  https://doi.org/10.1210/en.2005-0918CrossRefGoogle Scholar
  135. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27:2693–2703.  https://doi.org/10.1523/JNEUROSCI.4542-06.2007CrossRefGoogle Scholar
  136. Zhou X, Li JJ, Yu LC (2003) Plastic changes of calcitonin gene-related peptide in morphine tolerance: behavioral and immunohistochemical study in rats. J Neurosci Res 74:622–629.  https://doi.org/10.1002/jnr.10770CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Anne-Sophie Wattiez
    • 1
    • 2
  • Mengya Wang
    • 3
  • Andrew F. Russo
    • 1
    • 2
    • 4
    Email author
  1. 1.Department of Molecular Physiology and BiophysicsUniversity of IowaIowa CityUSA
  2. 2.Center for the Prevention and Treatment of Visual LossIowa VA Health Care SystemIowa CityUSA
  3. 3.Department of PharmacologyUniversity of IowaIowa CityUSA
  4. 4.Department of NeurologyUniversity of IowaIowa CityUSA

Personalised recommendations